Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models

被引：0
|
作者：
Izadi, Hooman [1 ]
Hoang, Tiffany [1 ]
Ibrahim, Noah [1 ]
Pinchman, Joseph [1 ]
Boren, Brant C. [1 ]
Ma, Jianhui [1 ]
de Jong, Petrus R. [1 ]
Li, Jiali [1 ]
Bunker, Kevin D. [1 ]
Samatar, Ahmed A. [1 ]
Donate, Fernando [1 ]
机构：
[1] Zentalis, San Diego, CA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2591
引用
收藏
页数：2
相关论文
共 35 条
  • [1] A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML)
    Smith, Catherine Choy
    Vachhani, Pankit
    Garcia-Manero, Guillermo
    Grieselhuber, Nicole Renee
    Murthy, Guru Subramanian Guru
    Bhatia, Astha
    Arora, Jatinder
    Izadi, Hooman
    Fiorino, Anthony
    Rampal, Raajit
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Tumor pharmacokinetics, pharmacodynamics and efficacy analysis of WEE1 inhibitor, zn-c3 in patient- derived xenograft models of glioblastoma
    Mehta, Shwetal
    Tien, An-Chi
    Patel, Sonam
    Margaryan, Tigran
    Shivanna, Anilkumar Thaghalli
    Elena, Leonel
    Molloy, Jennifer
    Knight, William
    Hon, Ruiheng
    Elliott, Mackenna
    Stavnichuk, Mariya
    Opachich, Zorana
    Chang, Yu-Wei
    Montgomery, Chelsea
    Himes, Sarah
    Hopkins, Barbara
    Tovmasyan, Artak
    Sanai, Nader
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3
    Chalasani, P.
    Tolcher, A.
    Meric-Bernstam, F.
    Mamdani, H.
    de Jong, P. R.
    Anderes, K.
    Samatar, A. A.
    Sergeeva, M.
    Gazdoiu, M.
    Viana, M. R.
    Pultar, P.
    Voliotis, D.
    Donate, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S593 - S593
  • [4] ZN-c3, a potent and selective Wee-1 inhibitor demonstrates anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance
    Li, Jiali
    Ma, Jianhui
    de Jong, Petrus R.
    Izadi, Hooman
    Hoang, Tiffany
    Ibrahim, Noah
    Boren, Brant
    Hegde, Sayee Hegde
    Donate, Fernando
    Samatar, Ahmed A.
    CANCER RESEARCH, 2022, 82 (12)
  • [5] The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates
    Ma, J.
    Guo, X.
    Lee, C.
    Meric-Bernstam, F.
    Harismendy, O.
    Jubb, A.
    Kim, D.
    Lackner, M. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S225 - S226
  • [6] The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor activity with KRASG12C inhibitors in multiple KRASG12C models
    Jameson, Nathan M.
    Kim, Gabriel
    Lee, Catherine
    Skrable, Blake
    Shea, Alexandra
    Abed, Monah
    Harismendy, Olivier
    Ma, Jianhui
    Kim, Doris
    Lackner, Mark R.
    CANCER RESEARCH, 2024, 84 (06)
  • [7] A phase I dose-escalation study of ZN-d5, an BCL-2 inhibitor with improved selectivity, in patients with advanced non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML)
    Zaucha, J. M.
    Fiorino, T.
    Kalro, A.
    Shin, H-J.
    Viiala, N.
    Torres, L.
    Gordon, G.
    Kirshoff, R.
    Lopez, S.
    Makris, L.
    Miller, C.
    Park, S.
    Voliotis, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S617 - S617
  • [8] The novel aurora kinase inhibitor AS703569 shows potent anti-tumor activity in acute myeloid leukemia (AML).
    Sarno, Samantha
    Shaw, Jamie
    Spooner, Edward
    Ma, Jianguo
    Clark, Ann
    Dumontet, Charles
    Romanelli, Angela
    BLOOD, 2007, 110 (11) : 279A - 279A
  • [9] THE COMBINATION OF SELINEXOR (KPT-330), A SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE), & THE FLT3 INHIBITOR QUIZATINIB SHOWS ANTI-TUMOR ACTIVITY IN ACUTE MYELOID LEUKEMIA (AML) IN VITRO AND IN VIVO
    Carlson, R.
    Senapedis, W.
    Landesman, Y.
    Shacham, S.
    HAEMATOLOGICA, 2014, 99 : 290 - 291
  • [10] Synergistic effect of BCL-2 inhibitor APG-2575 and CDK9 inhibitor in acute myeloid leukemia and DLBCL preclinical tumor models
    Fang, Douglas D.
    Tao, Ran
    Tang, Qiuqiong
    Gu, Shoulai
    Zhai, Guoqin
    Li, Jiajun
    Wang, Qixin
    Fang, Xu
    Li, Na
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2019, 79 (13)
1234